Novel Coronavirus (SARS-CoV-2/COVID-19)
On June 17 at 1 p.m. ET, the AHA and Avia Health Innovation will host a webinar during which experts will share how hospitals and health systems successfully have deployed digital solutions to provide access to behavioral health care treatment during the COVID-19 pandemic.
FDA released new guidance that expands for the duration of the COVID-19 emergency the availability and capability of non-invasive monitoring devices.
CMS released guidance for non-federal governmental plans implementing the Families First Coronavirus Response Act requirement to cover COVID-19 diagnostic testing and certain related items and services without cost-sharing, prior authorization or other medical management restrictions during the…
The Food and Drug Administration reissued emergency use authorizations that revise policy on the types of respirators that can be decontaminated for reuse.
This document outlines changes made by the Food and Drug Administration to its policy governing the decontamination and reuse of certain respirators during the COVID-19 public health emergency.
The Food and Drug Administration released COVID-19 performance data for four more antibody test kits. The results come from the first collaboration between FDA, the National Institute of Health’s National Cancer Institute, Centers for Disease Control and Prevention and Biomedical Advanced Research…
This guide provides participants with instructions and helpful tips for the Health Sector Cybersecurity Coordination Center (HC3) Cybersecurity Threat Briefing Series, hosted via WebEx. The WebEx link in the calendar invite enables participant access to the briefing. See related documents below.
In this podcast, Nancy Myers, vice president of leadership and system innovation at the AHA interviews, Nancy Combs, Henry Ford Health System’s director of community health integration.
The Department of Health and Human Services released guidance specifying what data laboratories must report to HHS along with their COVID-19 test results, the method for submission, and the data reporting and transmission requirements.
The Food and Drug Administration this week released guidance for institutional review boards seeking clarity regarding the key factors and procedures they should consider when reviewing requests by physicians and others for individual patient access to investigational drugs.